Romeo Giulio R, Lee Junhee, Mulla Christopher M, Noh Youngmin, Holden Casey, Lee Byung-Cheol
Joslin Diabetes Center, Boston, Massachusetts, US.
Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine Hospital, Dongdaemun-gu, Seoul, Republic of Korea.
J Endocr Soc. 2020 Jul 13;4(11):bvaa094. doi: 10.1210/jendso/bvaa094. eCollection 2020 Nov 1.
The identification of adjunct safe, durable, and cost-effective approaches to reduce the progression from prediabetes to type 2 diabetes (T2D) is a clinically relevant, unmet goal. It is unknown whether cinnamon's glucose-lowering properties can be leveraged in individuals with prediabetes.
The objective of this work is to investigate the effects of cinnamon on measures of glucose homeostasis in prediabetes.
This double-blind, placebo-controlled, clinical trial randomly assigned adult individuals meeting any criteria for prediabetes to receive cinnamon 500 mg or placebo thrice daily (n = 27/group). Participants were enrolled and followed at 2 academic centers for 12 weeks.
Primary outcome was the between-group difference in fasting plasma glucose (FPG) at 12 weeks from baseline. Secondary end points included the change in 2-hour PG of the oral glucose tolerance test (OGTT), and the change in the PG area under the curve (AUC) derived from the OGTT.
From a similar baseline, FPG rose after 12 weeks with placebo but remained stable with cinnamon, leading to a mean between-group difference of 5 mg/dL ( < .05). When compared to the respective baseline, cinnamon, but not placebo, resulted in a significant decrease of the AUC PG ( < .001) and of the 2-hour PG of the OGTT ( < .05). There were no serious adverse events in either study group.
In individuals with prediabetes, 12 weeks of cinnamon supplementation improved FPG and glucose tolerance, with a favorable safety profile. Longer and larger studies should address cinnamon's effects on the rate of progression from prediabetes to T2D.
确定安全、持久且具有成本效益的辅助方法以减少从糖尿病前期进展为2型糖尿病（T2D）是一个具有临床相关性但尚未实现的目标。目前尚不清楚肉桂的降血糖特性是否可用于糖尿病前期个体。
本研究旨在探讨肉桂对糖尿病前期个体葡萄糖稳态指标的影响。
设计、地点、参与者和干预措施：本双盲、安慰剂对照临床试验将符合任何糖尿病前期标准的成年个体随机分为两组，分别每日三次服用500毫克肉桂或安慰剂（每组n = 27）。参与者在两个学术中心登记入组并随访12周。
主要结局是12周时空腹血糖（FPG）相对于基线的组间差异。次要终点包括口服葡萄糖耐量试验（OGTT）中2小时血糖（PG）的变化，以及OGTT衍生的PG曲线下面积（AUC）的变化。
从相似的基线开始，安慰剂组在12周后FPG升高，而肉桂组保持稳定，导致组间平均差异为5毫克/分升（P <.05）。与各自的基线相比，肉桂组而非安慰剂组导致OGTT的AUC PG显著降低（P <.001）和2小时PG显著降低（P <.05）。两个研究组均未出现严重不良事件。
在糖尿病前期个体中，补充肉桂12周可改善FPG和葡萄糖耐量，且安全性良好。需要进行更长时间和更大规模的研究来探讨肉桂对从糖尿病前期进展为T2D的发生率的影响。
